Concepedia

TOPICAL APRACLONIDINE REDUCES PAIN AFTER INTRAVITREAL INJECTIONS

Oded Lagstein, Noa Ben-Artzi, Asaf Achiron, Achia Nemet, Maroun Khreish, Elisha Bartov, Zvia Burgansky–Eliash

Retina · 2016 · 11 citations · 14 references

DOI

Abstract

Topical apraclonidine 0.5%, administered 30 minutes before IViT, significantly decreased pain by a factor of 1.94. It did not decrease the incidence or size of SCH in the entire cohort, but only in several subpopulations.

References

14

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

Anne E. Fung, Philip J. Rosenfeld, Elias Reichel · British Journal of Ophthalmology · 2006 · 534 citations · Full text

, , +17

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

Lihteh Wu, María Ana Martinez-Castellanos, Hugo Quiroz–Mercado et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 2007 · 454 citations

, , +4

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

Paul Mitchell, Korobelnik Jf, Paolo Lanzetta et al. · British Journal of Ophthalmology · 2009 · 294 citations

Short-term Intraocular Pressure Changes Immediately After Intravitreal Injections of Anti–Vascular Endothelial Growth Factor Agents

Judy E. Kim, Anand V. Mantravadi, Elizabeth Y. Hur et al. · American Journal of Ophthalmology · 2008 · 243 citations

, , +9

Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study

Rogério A. Costa, Rodrigo Jorge, Daniela Calucci et al. · Investigative Ophthalmology & Visual Science · 2006 · 165 citations